Prostate Cancer Vaccines

Creative Biolabs is a world leader in the field of cancer vaccine development. With our extensive experience and advanced platform, we are therefore confident in offering the best services for prostate cancer vaccine development and guarantee the finest results for our customers all over the world.

Prostate Cancer

Prostate cancer is a type of cancer that occurs in the prostate, which is a gland of the male reproductive system. Most prostate cancers develop slowly. Cancer cells may spread from the prostate to other parts of the body, especially lymph nodes, and bones. It may initially cause no symptoms but at a later stage, it may cause dysuria, hematuria, back or pelvic pain. Other late-stage symptoms may include tiredness due to low red blood cell levels.

Therapeutic Vaccines for Prostate Cancer

Of the GU malignancies, prostate cancer has the fewest approved immunotherapies despite a variety of prostate cancer-specific antigens that are potential natural targets for immunotherapy. Although numerous clinical trials have been conducted investigating the role of various immunotherapeutics in prostate cancer, there is currently only one FDA approved immunotherapy in prostate cancer.

Sipuleucel-T

The only approved immunotherapy in prostate cancer is sipuleucel-T, which is approved in the metastatic castration-resistant prostate cancer (mCRPC) setting. Sipuleucel-T is an autologous dendritic cell vaccine that expresses a fusion protein of prostatic acid phosphatase (PAP) and GM-CSF. It is approved for the treatment of nonvisceral mCRPC in asymptomatic or minimally symptomatic patients on the basis of clinical trials demonstrating an OS benefit compared to placebo.

A patient’s peripheral blood mononuclear cells are extracted via leukapheresis, and CD54⁺ antigen-presenting cells (APCs) including DCs are isolated and exposed in vitro to a recombinant immunogenic fusion protein, PA2024, consisting of the PAP–GM-CSF fusion protein. These activated cells are subsequently infused into the patients approximately 3 days after being extracted with the goal of using the GM-CSF immune activation to stimulate the T cell immune response to the PAP antigen. The process is repeated every 2 weeks for a total of three treatments.

PSA-TRICOM (PROSTVAC-VF)

PSA-TRICOM is a vaccine that consists of fowl pox and vaccinia virus vectors containing the PSA gene and three co-stimulatory transgenes (leukocyte function-associated antigen 3, B7-1, and intracellular adhesion molecule 1). The hypothesis is that the PSA serves as an antigen, which in combination with co-stimulatory molecules can enhance the T cell cytotoxic response to prostate cancer.

GVAX

GVAX is a prostate cancer vaccine that is comprised of two irradiated prostate cancer cell lines (LNCaP and PC-3) genetically engineered to express GM-CSF. However, in October 2008, VITAL-2 was terminated when investigators declared that the study was unlikely to meet its primary end point. Regardless of the rationale, GVAX is not approved as a vaccine, highlighting the complexity of vaccine development and approval in advanced prostate cancer.

Creative Biolabs is a leader in the field of vaccine development and has focused on the cancer vaccines for years. We have experts who are able to help you with the development of the prostate cancer vaccines. If you are interested in our services, please contact us for more details.

All of our products can only be used for research purposes. These vaccine ingredients CANNOT be used directly on humans or animals.